Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > BIND Biosciences Presents Preclinical Data for Novel Nanomedicine, BIND-014, at American Chemical Society National Meeting

Abstract:
BIND Biosciences announced today the presentation of its Medicinal Nanoengineering™ platform at the ACS National Meeting, including results from preclinical studies on its lead nanomedicine drug, BIND-014, scheduled to enter clinical trials later this year.

BIND Biosciences Presents Preclinical Data for Novel Nanomedicine, BIND-014, at American Chemical Society National Meeting

Cambridge, MA | Posted on August 23rd, 2010

BIND-014 is a targeted, polymeric nanoparticle containing the cytotoxic agent, docetaxel, which is approved in major cancer indications, including breast, prostate and lung. In animal models of human cancers, BIND-014 was shown to deliver up to 20 times more docetaxel to the tumor site than an equivalent dose of Taxotere®. The increased accumulation of docetaxel at the site of disease was shown in preclinical models to lead to marked improvements in antitumor activity and tolerability.

At the ACS National Meeting, Dr. Jeff Hrkach, Senior Vice President of Pharmaceutical Sciences at BIND, will present the latest preclinical data showing the efficacy of BIND-014, as well as presenting results of preclinical studies using the company's Medicinal Nanoengineering proprietary technology for BIND's drug candidates in oncology, inflammatory diseases and cardiovascular disorders. The presentation will be part of a three-day symposium on the advancement of nanomedicine at the ACS National Meeting, taking place in Boston from August 22 through August 26. Dr. Hrkach's presentation, "High-precision therapeutics through Medicinal Nanoengineering," will be Tuesday, August 24 at 3:55 PM in The Westin Boston Waterfront, Grand Ballroom C.

In addition, both of BIND's scientific co-founders, Dr. Robert Langer, MIT David H. Koch Institute Professor, and Dr. Omid Farokhzad, Harvard Medical School Associate Professor, have been invited to present at the nanomedicine symposium at the ACS.

* Dr. Langer delivered the opening keynote address for the nanomedicine symposium, "Nanotechnology and its potential in medicine," on Sunday, August 22.

* Dr. Farokhzad will make a presentation, "Medical nanoengineering: Multifunctional polymeric nanoparticles for medical applications," on Monday, August 23, with the results and drug discovery translation of his pioneering academic research in nanomedicine technology.

"As our recent data show, BIND's Medicinal Nanoengineering approach has the potential to significantly improve upon the traditional drug development process and produce best-in-class new drugs," said Jeff Hrkach, Senior VP at BIND. "We have shown in preclinical studies with BIND-014 and other drug candidates that our platform can produce more effective, less toxic drugs by targeting our drug compounds precisely to the site of disease."

####

About BIND Biosciences
BIND Biosciences, Inc., is a biopharmaceutical company leveraging its proprietary Medicinal Nanoengineering platform to produce best-in-class drugs to provide significant improvement in the treatment of patients with serious diseases. BIND’s platform enables the design, engineering and manufacturing of therapeutic targeted nanoparticles with unprecedented control over drug pharmacokinetics, biodistribution and cell- or tissue-specific targeting. Medicinal Nanoengineering complements medicinal chemistry to enable predictable, cost effective and rapid development of breakthrough products with superior efficacy and safety profiles. Product opportunities include enabling or expediting the development of pipeline molecules as well as improving performance, expanding indications or life cycle extension for mid- and late-stage products. BIND’s initial product development efforts are in the areas of oncology, cardiovascular disorders, inflammatory disease and RNAi therapeutics. BIND is working both on nanoengineered forms of approved drugs and with pharmaceutical partners on drugs in development. BIND’s lead program, BIND-014, targets a surface protein upregulated in solid tumors and is planned to enter clinical development in 2H 2010.

BIND was founded in 2006 by two pioneers in the field of therapeutic targeted nanoparticles, Dr. Robert Langer and Dr. Omid Farokhzad. BIND is backed by leading venture capital firms, Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments and Endeavour Vision.

For more information, please click here

Contacts:
BIND Biosciences, Inc.
Andrea Franz, 617-491-3400

or
Media:
The Yates Network
Kathryn Morris, 845-635-9828

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Rutgers, NIST physicists report technology with potential for sub-micron optical switches March 31st, 2015

Prototype 'nanoneedles' generate new blood vessels in mice: Scientists have developed tiny 'nanoneedles' that have successfully prompted parts of the body to generate new blood vessels, in a trial in mice March 31st, 2015

Super sensitive measurement of magnetic fields March 31st, 2015

Nanomedicine pioneer Mauro Ferrari at ETH Zurich March 31st, 2015

Nanomedicine

Nanion Technologies Appoints James Costantin as Director of Customer Relations: Nanion is pleased to announce the appointment of Dr. James Costantin as Director of Customer Relations at Nanion Technologies Inc. March 31st, 2015

Nanomedicine shines light on combined force of nanomedicine and regenerative medicine March 31st, 2015

Prototype 'nanoneedles' generate new blood vessels in mice: Scientists have developed tiny 'nanoneedles' that have successfully prompted parts of the body to generate new blood vessels, in a trial in mice March 31st, 2015

Nanomedicine pioneer Mauro Ferrari at ETH Zurich March 31st, 2015

Announcements

Rutgers, NIST physicists report technology with potential for sub-micron optical switches March 31st, 2015

Prototype 'nanoneedles' generate new blood vessels in mice: Scientists have developed tiny 'nanoneedles' that have successfully prompted parts of the body to generate new blood vessels, in a trial in mice March 31st, 2015

Super sensitive measurement of magnetic fields March 31st, 2015

Nanomedicine pioneer Mauro Ferrari at ETH Zurich March 31st, 2015

Events/Classes

Nanomedicine pioneer Mauro Ferrari at ETH Zurich March 31st, 2015

State-of-the-art online system unveiled to pinpoint metrology software accuracy March 27th, 2015

LAMDAMAP 2015 hosted by the University March 26th, 2015

SUNY POLY CNSE to Host First Ever Northeast Semi Supply Conference (NESCO) Conference Will Connect New and Emerging Innovators in the Northeastern US and Canada with Industry Leaders and Strategic Investors to Discuss Future Growth Opportunities in NYS March 25th, 2015

Nanobiotechnology

From tobacco to cyberwood March 31st, 2015

Wrapping carbon nanotubes in polymers enhances their performance: Scientists at Japan's Kyushu University say polymer-wrapped carbon nanotubes hold much promise in biotechnology and energy applications March 30th, 2015

'Atomic chicken-wire' is key to faster DNA sequencing March 30th, 2015

Designer's toolkit for dynamic DNA nanomachines: Arm-waving nanorobot signals new flexibility in DNA origami March 27th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE